Methacholine

DB06709

small molecule approved investigational

Deskripsi

Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing symptoms such as difficulty breathing.A229598, A229603 Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M3 muscarinic receptors that stimulate ASM contraction.A229603, A229618, A229643 Methacholine is a non-specific cholinergic agonist (parasympathomimetic) that acts through muscarinic receptors in the lungs to induce bronchoconstriction.L31763 In patients with AHR, a lower dose of methacholine is required to induce bronchoconstriction, which forms the basis for the methacholine challenge test to diagnose AHR.A229648, L31763

Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.L31763

Struktur Molekul 2D

Berat 160.234
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food.

Interaksi Obat

363 Data
Esmolol Esmolol may increase the bronchoconstrictory activities of Methacholine.
Betaxolol Betaxolol may increase the bronchoconstrictory activities of Methacholine.
Metoprolol Metoprolol may increase the bronchoconstrictory activities of Methacholine.
Atenolol Atenolol may increase the bronchoconstrictory activities of Methacholine.
Timolol Timolol may increase the bronchoconstrictory activities of Methacholine.
Sotalol Sotalol may increase the bronchoconstrictory activities of Methacholine.
Propranolol Propranolol may increase the bronchoconstrictory activities of Methacholine.
Labetalol Labetalol may increase the bronchoconstrictory activities of Methacholine.
Bisoprolol Bisoprolol may increase the bronchoconstrictory activities of Methacholine.
Alprenolol Alprenolol may increase the bronchoconstrictory activities of Methacholine.
Pindolol Pindolol may increase the bronchoconstrictory activities of Methacholine.
Carvedilol Carvedilol may increase the bronchoconstrictory activities of Methacholine.
Propafenone Propafenone may increase the bronchoconstrictory activities of Methacholine.
Acebutolol Acebutolol may increase the bronchoconstrictory activities of Methacholine.
Nadolol Nadolol may increase the bronchoconstrictory activities of Methacholine.
Bevantolol Bevantolol may increase the bronchoconstrictory activities of Methacholine.
Practolol Practolol may increase the bronchoconstrictory activities of Methacholine.
Penbutolol Penbutolol may increase the bronchoconstrictory activities of Methacholine.
Oxprenolol Oxprenolol may increase the bronchoconstrictory activities of Methacholine.
Dexpropranolol Dexpropranolol may increase the bronchoconstrictory activities of Methacholine.
Celiprolol Celiprolol may increase the bronchoconstrictory activities of Methacholine.
Nebivolol Nebivolol may increase the bronchoconstrictory activities of Methacholine.
Bufuralol Bufuralol may increase the bronchoconstrictory activities of Methacholine.
Bopindolol Bopindolol may increase the bronchoconstrictory activities of Methacholine.
Bupranolol Bupranolol may increase the bronchoconstrictory activities of Methacholine.
Indenolol Indenolol may increase the bronchoconstrictory activities of Methacholine.
Arotinolol Arotinolol may increase the bronchoconstrictory activities of Methacholine.
Levobetaxolol Levobetaxolol may increase the bronchoconstrictory activities of Methacholine.
Talinolol Talinolol may increase the bronchoconstrictory activities of Methacholine.
Anisodamine Anisodamine may increase the bronchoconstrictory activities of Methacholine.
Bucindolol Bucindolol may increase the bronchoconstrictory activities of Methacholine.
Esatenolol Esatenolol may increase the bronchoconstrictory activities of Methacholine.
Cloranolol Cloranolol may increase the bronchoconstrictory activities of Methacholine.
Mepindolol Mepindolol may increase the bronchoconstrictory activities of Methacholine.
Epanolol Epanolol may increase the bronchoconstrictory activities of Methacholine.
Tertatolol Tertatolol may increase the bronchoconstrictory activities of Methacholine.
Landiolol Landiolol may increase the bronchoconstrictory activities of Methacholine.
Cimetropium Methacholine may decrease the anticholinergic activities of Cimetropium.
Pegvisomant The risk or severity of adverse effects can be increased when Pegvisomant is combined with Methacholine.
Mefloquine The risk or severity of adverse effects can be increased when Mefloquine is combined with Methacholine.
Tacrine The risk or severity of adverse effects can be increased when Tacrine is combined with Methacholine.
Sulpiride The risk or severity of adverse effects can be increased when Sulpiride is combined with Methacholine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Methacholine.
Cinchocaine The risk or severity of adverse effects can be increased when Cinchocaine is combined with Methacholine.
Pyridostigmine The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Methacholine.
Nizatidine The risk or severity of adverse effects can be increased when Nizatidine is combined with Methacholine.
Galantamine The risk or severity of adverse effects can be increased when Galantamine is combined with Methacholine.
Isoflurophate The risk or severity of adverse effects can be increased when Isoflurophate is combined with Methacholine.
Diethylcarbamazine The risk or severity of adverse effects can be increased when Diethylcarbamazine is combined with Methacholine.
Minaprine The risk or severity of adverse effects can be increased when Minaprine is combined with Methacholine.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Methacholine.
Demecarium The risk or severity of adverse effects can be increased when Demecarium is combined with Methacholine.
Physostigmine The risk or severity of adverse effects can be increased when Physostigmine is combined with Methacholine.
Rivastigmine The risk or severity of adverse effects can be increased when Rivastigmine is combined with Methacholine.
Edrophonium The risk or severity of adverse effects can be increased when Edrophonium is combined with Methacholine.
Procainamide The risk or severity of adverse effects can be increased when Procainamide is combined with Methacholine.
Memantine The risk or severity of adverse effects can be increased when Memantine is combined with Methacholine.
Ambenonium The risk or severity of adverse effects can be increased when Ambenonium is combined with Methacholine.
Ketamine The risk or severity of adverse effects can be increased when Ketamine is combined with Methacholine.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Methacholine.
Decamethonium The risk or severity of adverse effects can be increased when Decamethonium is combined with Methacholine.
Ginkgo biloba The risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Methacholine.
Neostigmine The risk or severity of adverse effects can be increased when Neostigmine is combined with Methacholine.
1,10-Phenanthroline The risk or severity of adverse effects can be increased when 1,10-Phenanthroline is combined with Methacholine.
Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Methacholine.
Huperzine A The risk or severity of adverse effects can be increased when Huperzine A is combined with Methacholine.
Phenserine The risk or severity of adverse effects can be increased when Phenserine is combined with Methacholine.
Regramostim The risk or severity of adverse effects can be increased when Regramostim is combined with Methacholine.
Aprotinin The risk or severity of adverse effects can be increased when Aprotinin is combined with Methacholine.
Betaine The risk or severity of adverse effects can be increased when Betaine is combined with Methacholine.
Capsaicin The risk or severity of adverse effects can be increased when Capsaicin is combined with Methacholine.
Coumaphos The risk or severity of adverse effects can be increased when Coumaphos is combined with Methacholine.
Dichlorvos The risk or severity of adverse effects can be increased when Dichlorvos is combined with Methacholine.
Fenthion The risk or severity of adverse effects can be increased when Fenthion is combined with Methacholine.
Metrifonate The risk or severity of adverse effects can be increased when Metrifonate is combined with Methacholine.
Acotiamide The risk or severity of adverse effects can be increased when Acotiamide is combined with Methacholine.
Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Methanesulfonyl Fluoride is combined with Methacholine.
Paraoxon The risk or severity of adverse effects can be increased when Paraoxon is combined with Methacholine.
Tyrothricin The risk or severity of adverse effects can be increased when Tyrothricin is combined with Methacholine.
Ipidacrine The risk or severity of adverse effects can be increased when Ipidacrine is combined with Methacholine.
Distigmine The risk or severity of adverse effects can be increased when Distigmine is combined with Methacholine.
Tretamine The risk or severity of adverse effects can be increased when Tretamine is combined with Methacholine.
Posiphen The risk or severity of adverse effects can be increased when Posiphen is combined with Methacholine.
Methylphosphinic Acid The risk or severity of adverse effects can be increased when Methylphosphinic Acid is combined with Methacholine.
Capreomycin The therapeutic efficacy of Methacholine can be decreased when used in combination with Capreomycin.
Framycetin The therapeutic efficacy of Methacholine can be decreased when used in combination with Framycetin.
Amikacin The therapeutic efficacy of Methacholine can be decreased when used in combination with Amikacin.
Tobramycin The therapeutic efficacy of Methacholine can be decreased when used in combination with Tobramycin.
Gentamicin The therapeutic efficacy of Methacholine can be decreased when used in combination with Gentamicin.
Netilmicin The therapeutic efficacy of Methacholine can be decreased when used in combination with Netilmicin.
Neomycin The therapeutic efficacy of Methacholine can be decreased when used in combination with Neomycin.
Streptomycin The therapeutic efficacy of Methacholine can be decreased when used in combination with Streptomycin.
Kanamycin The therapeutic efficacy of Methacholine can be decreased when used in combination with Kanamycin.
Paromomycin The therapeutic efficacy of Methacholine can be decreased when used in combination with Paromomycin.
Ribostamycin The therapeutic efficacy of Methacholine can be decreased when used in combination with Ribostamycin.
Geneticin The therapeutic efficacy of Methacholine can be decreased when used in combination with Geneticin.
Apramycin The therapeutic efficacy of Methacholine can be decreased when used in combination with Apramycin.
Gentamicin C1a The therapeutic efficacy of Methacholine can be decreased when used in combination with Gentamicin C1a.
Neamine The therapeutic efficacy of Methacholine can be decreased when used in combination with Neamine.
Arbekacin The therapeutic efficacy of Methacholine can be decreased when used in combination with Arbekacin.

Target Protein

Muscarinic acetylcholine receptor M3 CHRM3
Muscarinic acetylcholine receptor M2 CHRM2
Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M4 CHRM4
Muscarinic acetylcholine receptor M5 CHRM5

Referensi & Sumber

Artikel (PubMed)
  • PMID: 30306206
    Aghasafari P, George U, Pidaparti R: A review of inflammatory mechanism in airway diseases. Inflamm Res. 2019 Jan;68(1):59-74. doi: 10.1007/s00011-018-1191-2. Epub 2018 Oct 10.
  • PMID: 31183836
    Lam M, Lamanna E, Bourke JE: Regulation of Airway Smooth Muscle Contraction in Health and Disease. Adv Exp Med Biol. 2019;1124:381-422. doi: 10.1007/978-981-13-5895-1_16.
  • PMID: 23691511
    Castro JM, Resende RR, Mirotti L, Florsheim E, Albuquerque LL, Lino-dos-Santos-Franco A, Gomes E, de Lima WT, de Franco M, Ribeiro OG, Russo M: Role of m2 muscarinic receptor in the airway response to methacholine of mice selected for minimal or maximal acute inflammatory response. Biomed Res Int. 2013;2013:805627. doi: 10.1155/2013/805627. Epub 2013 Apr 18.
  • PMID: 14993104
    Gosens R, Bromhaar MM, Tonkes A, Schaafsma D, Zaagsma J, Nelemans SA, Meurs H: Muscarinic M(3) receptor-dependent regulation of airway smooth muscle contractile phenotype. Br J Pharmacol. 2004 Mar;141(6):943-50. doi: 10.1038/sj.bjp.0705709. Epub 2004 Mar 1.
  • PMID: 21091801
    Gonzalez JC, Albinana E, Baldelli P, Garcia AG, Hernandez-Guijo JM: Presynaptic muscarinic receptor subtypes involved in the enhancement of spontaneous GABAergic postsynaptic currents in hippocampal neurons. Eur J Neurosci. 2011 Jan;33(1):69-81. doi: 10.1111/j.1460-9568.2010.07475.x. Epub 2010 Nov 23.
  • PMID: 3998816
    Meyer EM, Otero DH: Pharmacological and ionic characterizations of the muscarinic receptors modulating 3Hacetylcholine release from rat cortical synaptosomes. J Neurosci. 1985 May;5(5):1202-7.
  • PMID: 10335008
    Tulic MK, Wale JL, Petak F, Sly PD: Muscarinic blockade of methacholine induced airway and parenchymal lung responses in anaesthetised rats. Thorax. 1999 Jun;54(6):531-7. doi: 10.1136/thx.54.6.531.
  • PMID: 12611815
    Borchers MT, Biechele T, Justice JP, Ansay T, Cormier S, Mancino V, Wilkie TM, Simon MI, Lee NA, Lee JJ: Methacholine-induced airway hyperresponsiveness is dependent on Galphaq signaling. Am J Physiol Lung Cell Mol Physiol. 2003 Jul;285(1):L114-20. doi: 10.1152/ajplung.00322.2002. Epub 2003 Feb 28.
Menampilkan 8 dari 10 artikel.

Contoh Produk & Brand

Produk: 35 • International brands: 0
Produk
  • Methacholine Chloride, USP
    Powder, for solution • 100 mg / vial • Respiratory (inhalation) • Canada • Approved
  • Methacholine Chloride, USP
    Powder, for solution • 160 mg / vial • Respiratory (inhalation) • Canada • Approved
  • Methacholine Chloride, USP
    Powder, for solution • 320 mg / vial • Respiratory (inhalation) • Canada • Approved
  • Methacholine Chloride, USP
    Powder, for solution • 1280 mg / vial • Respiratory (inhalation) • Canada • Approved
  • Methacholine Chloride, USP
    Powder, for solution • 1600 mg / vial • Respiratory (inhalation) • Canada • Approved
  • Methacholine Omega
    Powder, for solution • 100 mg / vial • Respiratory (inhalation) • Canada • Approved
  • Methacholine Omega
    Powder, for solution • 1600 mg / vial • Respiratory (inhalation) • Canada • Approved
  • Methacholine Omega
    Powder, for solution • 480 mg / vial • Respiratory (inhalation) • Canada • Approved
Menampilkan 8 dari 35 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul